Edition:
India

Keryx Biopharmaceuticals Inc (KERX.OQ)

KERX.OQ on NASDAQ Stock Exchange Capital Market

4.64USD
15 Dec 2017
Change (% chg)

$0.06 (+1.31%)
Prev Close
$4.58
Open
$4.59
Day's High
$4.77
Day's Low
$4.47
Volume
3,387,997
Avg. Vol
415,345
52-wk High
$8.37
52-wk Low
$4.33

Latest Key Developments (Source: Significant Developments)

U.S. FDA approves Auryxia tablets as treatment for people with iron deficiency anemia and chronic kidney disease
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Keryx Biopharmaceuticals Inc :U.S. FDA approves Auryxia® (ferric citrate) tablets as a treatment for people with iron deficiency anemia and chronic kidney disease, not on dialysis.  Full Article

Keryx Biopharmaceuticals Q3 loss per share $0.20
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Keryx Biopharmaceuticals Inc :Keryx Biopharmaceuticals announces third quarter 2017 financial results.Q3 loss per share $0.20.Q3 revenue $15 million versus I/B/E/S view $17.9 million.Q3 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S.Keryx Biopharmaceuticals Inc- ‍cash and cash equivalents as of Sept 30, 2017 totaled $114.0 million compared to $111.8 million as of Dec 31, 2016​.  Full Article

Keryx Biopharmaceuticals withdraws 2016 financial guidance
Monday, 1 Aug 2016 

Keryx Biopharmaceuticals Inc : Company withdraws its 2016 financial guidance . Company announces interruption in supply of Auryxia(ferric citrate) . Supply interruption does not affect safety profile of currently available Auryxia . Expects to make Auryxia available to patients when supply of Auryxia is back to adequate levels . Total revenues for quarter ended June 30, 2016 were about $9.3 million, compared with $2.5 million last year . Supply of Auryxia is expected to be back to adequate levels during Q4 of 2016 . Expects to file a supplemental new drug application (SNDA) with FDA late in Q3 of 2016 . Determined supply interruption is going to occur due to production-related issue in converting API to finished product at contract manufacturer . Current inventories of Auryxia are not sufficient to ensure uninterrupted patient access to this medicine . Issue resulted in variable production yields of finished drug product and company has exhausted its reserve of finished drug product . Says at this time, current inventories of Auryxia are not sufficient to ensure uninterrupted patient access to Auryxia . Says supply interruption does not affect safety profile of currently available Auryxia . Working with its existing manufacturer to resolve production-related issue and rebuild adequate supply . "We believe we are well positioned financially to manage through this interruption in supply of Auryxia".  Full Article

The Baupost Group L.L.C. reports 42.53 pct stake in Keryx Biopharmaceuticals - SEC filing
Thursday, 2 Jun 2016 

The Baupost Group, L.L.C. : The Baupost Group, L.L.C. reports 42.53% stake in Keryx Biopharmaceuticals Inc as of May 27, 2016 - SEC FILING .The Baupost Group, L.L.C. had earlier reported a 34.61%stake in Keryx Biopharmaceuticals Inc as of October 14, 2015.  Full Article